louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07001943: Correlation Study Between SMA Blood Flow Reactivity and Acute Gastrointestinal Injury in Critically Ill Patients
Official title: Correlation Study Between SMA Blood Flow Reactivity and Acute Gastrointestinal Functional Injury in Critically Ill Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Intestinal Ischemia
Critical Illness
Enteral Nutrition Feeding
Hemodynamics
Ultrasonography, Doppler
Keywords: Enteral Nutrition
Critical Illness
Intestinal Ischemia
Hemodynamics
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2025-06-03
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will be selected from adult patients admitted to the ICU. Participants will be those aged between 18 and 80 years old, with an expected ICU stay of more than 72 hours after enrolled, and who require the initiation of enteral nutrition support. These patients are at risk of gastrointestinal dysfunction and acute gastrointestinal injury (AGI), making them suitable candidates for a study focused on optimizing enteral nutrition strategies and monitoring gastrointestinal blood flow.

Brief summary: This study aims to address the challenges of enteral nutrition support in critically ill ICU patients with varying gastrointestinal function. We'll use bedside Doppler ultrasound to monitor superior mesenteric artery (SMA) blood flow changes post - feeding, exploring its correlation with Acute Gastrointestinal Injury (AGI) and other hemodynamic indicators. Our goals are to identify the patterns of SMA blood flow changes, establish a predictive model linking SMA blood flow reactivity to AGI risk, and propose individualized enteral nutrition strategies based on intestinal hemodynamics. Through this innovative approach, we hope to enhance the safety of enteral nutrition, reduce AGI incidence, and improve patient outcomes.


Eligibility criteria: Inclusion Criteria:

* Adults aged ≥18 years and ≤80 years.
* Admitted to the study with a expected stay of more than 72 hours.
* Require initiation of enteral nutrition support.

Exclusion Criteria:

* Pre-existing severe gastrointestinal diseases.
* Patients with gastrointestinal bleeding.
* Patients with bowel obstruction.
* Pregnant or lactating women.
* Patients with contraindications to bedside Doppler ultrasound.

Primary outcomes:
measure: feeding intolerance
timeFrame: From enrollment to the end of treatment at 3 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02168543: 1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers
Official title: Clinical Efficacy of Subgingivally Delivered 1% Alendronate in the Treatment of Smokers With Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Periodontitis
Lead sponsor: Government Dental College and Research Institute, Bangalore
Sponsor class: OTHER
First posted: 2014-06-20
Enrollment: 46
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * Locally delivered Alendronate (ALN) have potent inhibitory effect on bone and increases new bone formation in chronic periodontitis patients
* Till date no study has reported the effect of local delivery of ALN in chronic periodontitis patients among smokers. Hence the aim of this study is to investigate the clinical and radiographic effects of locally delivered ALN as an adjunct to the non surgical treatment in smoker chronic periodontitis patients.


Eligibility criteria: Inclusion Criteria:

* Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
* No history of periodontal therapy in preceding last 6 months
* No use of antibiotics in the preceding 6 months

Exclusion Criteria:

* Subjects with known systemic disease
* Known or suspected allergy to the ALN/bisphosphonate group
* Those on systemic ALN/bisphosphonate therapy
* Subjects with aggressive periodontitis,
* Use of smokeless tobacco in any form,
* Alcoholics
* Immunocompromised subjects
* Pregnant or lactating females

Primary outcomes:
measure: Change from baseline plaque scores at 2 month and 6 month
timeFrame: At baseline, 2nd month and 6th month
measure: Change from baseline gingival scores at 2 month and 6 month
timeFrame: At baseline, 2nd month and 6th month
Secondary outcomes:
measure: Change from baseline Probing depth at 2 month and 6 month
timeFrame: At baseline, 2nd month and 6th month
measure: Change from baseline Periodontal attachment level at 2 month and 6 month
timeFrame: At baseline, 2nd month and 6th month
measure: Change from baseline intrabony defect depth at 6 month
timeFrame: At baseline and 6th month
Other outcomes:
Locations:
Study officials:
affiliation: RIMS, Ranchi
name: Dr. Anuj Sharma, BDS, MDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02806843: Robot-Assisted Stroke Rehabilitation Based on Patient-Therapist Interactions
Official title: Robot-Assisted Stroke Rehabilitation Based on Patient-Therapist Interactions
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Stroke
Hemiplegia
Healthy
Keywords: stroke
hemiplegia
healthy
robotics
rehabilitation
therapy
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2016-06-21
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Our study goal is to assess natural patient-therapist interactions in order to map such human-human activities to robot-human interactions. Critical to accomplishing this mapping will be determining the feasibility of a humanoid robot interacting with a patient in a more intuitive and flexible way, while concomitantly investigating the issue of safe contact and release.

Detailed description: Stroke survivors with varying levels of motor deficit impairment in their upper extremity (UE) will be assessed using standardized clinical scales for cognition and motor impairment. Following assessment, the patient and therapist will complete a therapy session consisting of activities of daily living (ADL).

During the therapy session, visual 3D motion tracking will be used via Kinect, audio will be recorded, and basic measurements (i.e. the distance between a participants wrist and elbow) will be taken. After the patient-therapist interaction has been mapped, members of the research team will build computer based models of the therapist and patient using the insights gained from the human-human interaction. The models developed in this proposed study will be used as a template for programming safe and intuitive humanoid-patient interactions for future study. The model of the therapist will be implemented on the Robot (w/o a patient involved) and in a simulation environment where it will be tested with a computer-based model of the patient.

Eligibility criteria: Inclusion Criteria:

* Stroke survivors 18 years of age with hemiplegia and varying levels of impairment
* Healthy subjects greater than 18 years of age with no motor disabilities

Exclusion Criteria:

* Under 18 years of age

Primary outcomes:
measure: Patient-Therapist Interaction Mapping
timeFrame: 1 session, about 2 hours in length
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Penn Medicine Rittenhouse
state: Pennsylvania
Study officials:
affiliation: Penn Medicine Rittenhouse
name: Michelle J Johnson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01857843: Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe/ Simvastatin (Vytorin®) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coronary Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Coronary Syndrome
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-05-20
Enrollment: 160
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: To evaluate the early effects of intensive lipid lowering treatments with ezetimibe/simvastatin (Vytorin®) for each component of coronary plaques.

Study Design

* Prospective, randomized, single-center study of each 80 subjects enrolled
* Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria will be enrolled.
* Eligible subjects will be randomized 1:1 to A) Ezetimibe/Simvastatin (n=80) vs. B) Pravastatin (n=80), and each group of patients will be randomized further in a ratio of 1:1 to a) ZES (n=40) vs. b) EES (n=40), according to the type of stent used.
* All subjects will undergo VH-IVUS at initial procedure.
* Follow-up VH-IVUS will be performed at 3 months after index procedure. OCT at initial procedure and 3-months will be performed in available cases.


Eligibility criteria: Inclusion Criteria:

General inclusion criteria

1. Acute coronary syndrome including unstable angina, acute non-ST elevation myocardial infarction and acute ST elevation myocardial infarction
2. Age of 20 years or older
3. Patients with signed informed consent

Angiographic inclusion criteria

1. De novo lesion without significant plaque (angiographic lumen diameter stenosis \< 50%)
2. Reference vessel diameter ?\> 3.0 mm by operator assessment
3. Segment length of 10-20 mm
4. Distance from the PCI site \> 5.0mm (either proximal or distal)
5. Available for serial high quality IVUS studies of the entire segment.

Exclusion Criteria:

1. Failed PCI
2. Recommended coronary artery bypass grafting (CABG)
3. Cardiogenic Shock
4. Administration of lipid lowering agents before enrollment
5. Significant hepatic dysfunction (3 times normal reference values)
6. Significant renal dysfunction (Serum creatinine \> 2.0 mg/dl)
7. Significant leukopenia, thrombocytopenia, anemia, or known bleeding diathesis
8. Pregnant women or women with potential childbearing
9. Saphenous vein graft

Primary outcomes:
measure: Quantitative change in fibrofatty component of plaque measured by VH-IVUS
timeFrame: baseline and 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
Clinical trial NCT02316743: Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism
Official title: Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Systolic Heart Failure
Sub-clinical Hypothyroidism
Lead sponsor: Université de Sherbrooke
Sponsor class: OTHER
First posted: 2014-12-15
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether levothyroxine supplementation is beneficial in patients with systolic heart failure and subclinical hypothyroidism on the functional class evaluated with a 6 minute walk test.

Detailed description: Forty patients with systolic heart failure and subclinical hypothyroidism will be include in a open label trial. They will receive levothyroxine supplementation to determine if their functional class will be affect.

Eligibility criteria: Inclusion Criteria:

* Biochemical diagnosis of subclinical hypothyroidism (TSH between 3.5 and 10 with a normal T4)
* Systolic heart failure with New-York Heart Association (NYHA) class II or III
* Left ventricular ejection fraction under 40%
* Stable heart failure for the past 3 months (no IV furosemide or hospital admission)
* Beta-blockers and ACE inhibitors titrated to the maximum tolerated dose

Exclusion Criteria:

* Isolated diastolic heart failure
* Awaiting cardiac resynchronisation therapy
* Impossibility to perform the 6 minutes walk test
* Active cancer / Life expectancy under 18 months
* Treatment with amiodarone

Primary outcomes:
measure: Performance at the 6 minutes walk test
timeFrame: 6 months
Secondary outcomes:
measure: Difference of the brain natriuretic peptide measurement
timeFrame: 6 months
measure: Difference of activin a measurement
timeFrame: 6 months
measure: Difference of myostatin measurement
timeFrame: 6 months
measure: Increase in heart rate measurement
timeFrame: 6 months
measure: Difference of systolic and diastolic function on transthoracic echocardiogram
timeFrame: 6 months
measure: Arhythmic (ventricular arrhythmias and supraventricular arrythmias) and ischemic events (myocardial infarction, unstable angina and hospitalization for revascularization)
timeFrame: 6 months
measure: Normalisation of thyroid workup
timeFrame: 6 months
Other outcomes:
Locations:
city: Sherbrooke
country: Canada
facility: Centre Hospitalier Universitaire de Sherbrooke
state: Quebec
Study officials:
affiliation: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
name: Michel Nguyen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00244543: Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
Official title: A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Allergic Conjunctivitis
Keywords: ocular, allergic conjunctivitis, ophthalmic
Lead sponsor: Vistakon Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2005-10-26
Enrollment: 110
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis


Eligibility criteria: Inclusion Criteria:

history of ocular allergies and a positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months; calculated best-corrected visual acuity of 0.6 logMar or better in each eye; positive bilateral conjunctival allergy challenge reaction

-

Exclusion Criteria:

narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium or diagnosis of dry eye; ocular surgical intervention within 3 months; history of refractive surgery within 6 months; known history of retinal detachment, diabetic retinopathy, or progressive retinal disease; presence of active ocular infection positive history of an ocular herpetic infection; preauricular lymphadenopath; manifest signs or symptoms of clinically active allergic conjunctivitis

Primary outcomes:
measure: Ocular itching and conjunctival redness post challenge
Secondary outcomes:
measure: Ciliary and episcieral redness; chemosis; lid swelling; tearing; ocular mucous discharge; and nasal symptoms. All measured postchallenge
Other outcomes:
Locations:
city: North Andover
country: United States
state: Massachusetts
Study officials:
affiliation: Johnson & Johnson
name: Ingerman Avner, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05106543: Immediate Effect Of Kinesiological Taping
Official title: Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemiplegia
Keywords: Hemiplegia
Kinesiology taping
Functionality
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2021-11-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: In this study, it is aimed to examine the immediate effect of kinesiological taping on functionality in hemiplegic patients. 40 hemiplegic patients with a mean age of 63±15 years were included to the study. The patients were divided into two groups using the computerized randomization method. Kinesiology tape was applied to the 1st group (study group), and a patch tape was applied to the 2nd group (control group). The demographic and physical characteristics of the people who agreed to participate in the study were recorded. In both groups; before taping, right after taping, 45 min. after and 4 days after taping Timed Get Up and Go Test (TUG) were administered. Both groups were asked not to remove the tapes at the end of the 4th day.


Eligibility criteria: Inclusion Criteria:

* agree to participate in the study after detailed information about the study,
* to have sufficient cognitive functions, to be diagnosed with hemiplegia by a specialist physician,
* to be 18 years of age or older

Exclusion Criteria:

* Diagnosis of other neurological diseases (Parkinson's, Multiple Sclerosis, etc.),
* cancer other than hemiplegia, heart failure, surgery in the area to be applied,
* vascular problems in the lower extremity,
* chronic kidney failure,
* infection.

Primary outcomes:
measure: Immadiate Effect Of Kinesiological Taping
timeFrame: 4 days
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients
city: Istanbul
country: Turkey
facility: Okan University
Study officials:
affiliation: Okan University
name: emine atici, pt phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04461743: Microcirculation Evolution in Patients After Cardiac Surgery
Official title: Microcirculation Evolution in Patients After Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patients After Cardiac Surgery
Keywords: microcirculation
cardiac surgery
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2020-07-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients after cardiac surgery who required mechanical ventilation and for whom sublingual microcirculation measurements were possible.

Brief summary: We evaluated the impact on macrocirculatory hemodynamics and microcirculation in patients after cardiac surgery and compared the evolutions of those parameters between patients with tissue hypoperfusion and normal perfusion. Consecutive patients after cardiac surgery who required mechanical ventilation and for whom sublingual microcirculation measurements were possible enrolled.

Detailed description: We evaluated the impact on macrocirculatory hemodynamics and microcirculation in patients after cardiac surgery and compared the evolutions of those parameters between patients with tissue hypoperfusion and normal perfusion.

Eligibility criteria: Inclusion Criteria:

* Consecutive patients after cardiac surgery.
* Patients whom sublingual microcirculation measurements were possible.

Exclusion Criteria:

* moribund patients

Primary outcomes:
measure: Microcirculation
timeFrame: Extubation
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Department of Critical Care Medicine
state: Jiangsu
Study officials:
affiliation: Southeast University
name: Jingyuan Xu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00893243: Efficacy Comparative Study Between Tears Again®, Opticol® and Optive®
Official title: Efficacy Comparative Study Between Tears Again®, o Opticol® e o Optive® in Clinical and Symptomatology Treatment of Dry Eye Syndrome in Contact Lens Wearers and/or Computers Users
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dry Eye Syndrome
Lead sponsor: Hospital de Sao Sebastiao
Sponsor class: OTHER
First posted: 2009-05-05
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Administrative staff of the hospital with more than 4 hours/day computer use and contact lens wearers

Brief summary: Primary Purpose:

* To compare the efficacy in treating dry eye syndrome in contact lens wearers or computer users of Tears Again® versus Opticol® versus Optive®

Secondary Purpose:

* Subjective evaluation of symptomatology
* Evaluation of preference in different kind of administration - spray versus monodoses versus multi-doses


Eligibility criteria: Inclusion Criteria:

* Informed Consent signed
* Age \>18 years and \< 55 years
* Daily wearer of soft contact lens and/or daily (\> 4 hours/day) computer user

Exclusion Criteria:

* Dry eye Syndrome other than of evaporative etiology, according to DEWS
* Ocular or systemic disease that can affect the normal tear film
* Pregnancy or pregnancy risk (no contraceptive method), lactation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Santa maria da Feira
country: Portugal
facility: Serviço de Oftalmologia, Hospital de São Sebastião
Study officials:
affiliation: Ophthalmologist
name: Lilianne Duarte, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ophthalmology Department Director
name: José Salgado-Borges, PhD
role: STUDY_DIRECTOR
References: